On the basis of the results observed for the principal efficacy measure, there is a 1.1 percent probability of a true risk reduction of 10 percent or more. Moreover, dalcetrapib experienced concordantly neutral results on all the different parts of the primary end point and on the rate of coronary revascularization. In summary, the addition of dalcetrapib to regular therapy after an severe coronary syndrome raised the degrees of HDL cholesterol and apolipoprotein A1 and had minimal results on levels of LDL cholesterol and apolipoprotein B. Furthermore, triglyceride levels increased less in the dalcetrapib group than in the placebo group.PGAs target the secondary uveoscleral outflow system, which is not the diseased tissue in glaucoma.7 and 6.2 mmHg on days 28 and 14, respectively. That is significant provided that nearly all glaucoma patients have got low to moderately elevated IOPs of 26 mmHg or below during diagnosis. The trials will measure efficacy over 90 days and safety over 12 months. You will have two trials executed in the U.S., and one safety-only study in Canada.